Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuveen Select Tax-Free Income Portfolio is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of United States. The fund invests in the investment-grade municipal securities rated Baa and BBB or better. It benchmarks the performance of its portfolio against the Standard & Poor's (S&P) National Municipal Bond Index and Lipper General and Insured Unleveraged Municipal Debt Funds Average. Nuveen Select Tax-Free Income Portfolio was formed on March 19, 1992 and is domiciled in the United States.

Nuveen Select Tax-Free Income Portfolio

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHICAGO--(BUSINESS WIRE)--SHAREHOLDERS OF THE NUVEEN SELECT TAX-FREE INCOME PORTFOLIO (NYSE: NXP), NUVEEN CALIFORNIA SELECT TAX-FREE INCOME PORTFOLIO (NYSE: NXC), AND NUVEEN NEW YORK SELECT TAX-FREE INCOME PORTFOLIO (NYSE: NXN) HAVE APPROVED THE FUNDS' REORGANIZATION. THE REORGANIZATION WILL COMBINE NXC AND NXN INTO NXP. SUBJECT TO THE SATISFACTION OF CERTAIN CUSTOMARY CLOSING CONDITIONS, THE TRANSACTIONS ARE EXPECTED TO BECOME EFFECTIVE BEFORE THE MARKET OPENS ON JANUARY 12, 2026. THE MONTHLY.

NUVEEN SELECT TAX-FREE INCOME PORTFOLIOS ANNOUNCE SHAREHOLDER APPROVAL OF REORGANIZATION

THE STUDY IS DESIGNED TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED (EGFR MUT+) NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE CANCERS INITIALLY RESPONDED TO TREATMENT WITH OSIMERTINIB BUT SUBSEQUENTLY ACQUIRED RESISTANCE TO TREATMENT THE STUDY IS DESIGNED TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED (EGFR MUT+) NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE CANCERS INITIALLY RESPONDED TO TREATMENT WITH OSIMERTINIB BUT SUBSEQUENTLY ACQUIRED RESISTANCE TO TREATMENT

NUVECTIS PHARMA ANNOUNCES THE INITIATION OF THE PHASE 1B STUDY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH NSCLC

FORT LEE, NJ, NOV. 25, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT, THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A VIRTUAL KEY OPINION LEADER MEETING ON TUESDAY, DECEMBER 2, 2025 AT 8:00 AM ET TO DISCUSS THE NXP900 PHASE 1B PROGRAM IN ADVANCED SOLID TUMORS, INCLUDING THE COMBINATION WITH OSIMERTINIB IN NON-SMALL CELL LUNG CANCER. TO REGISTER FOR THE EVENT, CLICK HERE.

NUVECTIS PHARMA TO HOST A VIRTUAL KEY OPINION LEADER MEETING TO DISCUSS THE NXP900 PHASE 1B PROGRAM IN ADVANCED SOLID TUMORS, INCLUDING THE COMBINATION WITH OSIMERTINIB IN NSCLC

EINDHOVEN, THE NETHERLANDS, OCT. 29, 2025 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY ANNOUNCED ITS INDUSTRY-FIRST ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY (EIS) BATTERY MANAGEMENT CHIPSET WITH HARDWARE-BASED NANOSECOND-LEVEL SYNCHRONIZATION OF ALL DEVICES. THE NEW SYSTEM SOLUTION IS DESIGNED TO ENHANCE SAFETY, LONGEVITY, AND PERFORMANCE IN ELECTRIC VEHICLES AND ENERGY STORAGE SYSTEMS. IT INTEGRATES EIS MEASUREMENT DIRECTLY INTO THREE BATTERY MANAGEMENT SYSTEM (BMS) CHIPSET UNITS, ENABLING CARMAKERS TO GAIN DEEPER INSIGHTS INTO BATTERY HEALTH AND BEHAVIOR.

NXP IMPROVES BATTERY HEALTH MONITORING WITH EIS CAPABLE BATTERY MANAGEMENT CHIPSET

EINDHOVEN, THE NETHERLANDS, OCT. 28, 2025 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) HAS ANNOUNCED THE COMPLETION OF ITS ACQUISITIONS OFAVIVA LINKS, AND KINARA.

NXP COMPLETES ACQUISITIONS OF AVIVA LINKS AND KINARA TO ADVANCE AUTOMOTIVE CONNECTIVITY AND AI AT THE INTELLIGENT EDGE

EINDHOVEN, THE NETHERLANDS, OCT. 09, 2025 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY ANNOUNCED IT WILL RELEASE FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 AFTER THE CLOSE OF NORMAL TRADING ON THE NASDAQ GLOBAL SELECT MARKET ON MONDAY, OCTOBER 27, 2025. THE COMPANY WILL HOST A CONFERENCE CALL WITH THE FINANCIAL COMMUNITY ON TUESDAY, OCTOBER 28, 2025, AT 8:00 A.M. U.S. EASTERN DAYLIGHT TIME (EDT).

NXP SEMICONDUCTORS ANNOUNCES CONFERENCE CALL TO REVIEW THIRD QUARTER 2025 FINANCIAL RESULTS

EINDHOVEN, THE NETHERLANDS, AUG. 28, 2025 (GLOBE NEWSWIRE) -- AS PART OF ITS ONGOING CAPITAL RETURN PROGRAM, NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED THE PAYMENT OF AN INTERIM DIVIDEND. THE ACTIONS ARE BASED ON THE CONTINUED AND SIGNIFICANT STRENGTH OF THE NXP CAPITAL STRUCTURE, AND THE BOARD'S CONFIDENCE IN THE COMPANY'S ABILITY TO DRIVE LONG-TERM GROWTH AND STRONG CASH FLOW.

NXP SEMICONDUCTORS ANNOUNCES QUARTERLY DIVIDEND

EINDHOVEN, THE NETHERLANDS, AUG. 12, 2025 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ:NXPI) (TOGETHER WITH ITS SUBSIDIARIES, NXP) ANNOUNCED TODAY THE PRICING OF AN OFFERING BY ITS SUBSIDIARIES NXP B.V., NXP FUNDING LLC AND NXP USA, INC. (TOGETHER, THE ISSUERS) OF $500,000,000 AGGREGATE PRINCIPAL AMOUNT OF 4.300% SENIOR UNSECURED NOTES DUE 2028 (THE 2028 NOTES), $300,000,000 AGGREGATE PRINCIPAL AMOUNT OF 4.850% SENIOR UNSECURED NOTES DUE 2032 (THE 2032 NOTES) AND $700,000,000 AGGREGATE PRINCIPAL AMOUNT OF 5.250% SENIOR UNSECURED NOTES DUE 2035 (THE 2035 NOTES AND, COLLECTIVELY WITH THE 2028 NOTES AND THE 2032 NOTES, THE NOTES).

NXP SEMICONDUCTORS ANNOUNCES PRICING OF SENIOR UNSECURED NOTES OFFERING

THE PHASE 1B PROGRAM IS DESIGNED TO EVALUATE THE CLINICAL ACTIVITY OF NXP900 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS WHOSE CANCERS HARBOR SPECIFIC GENETIC ALTERATIONS, AND IN COMBINATION WITH EGFR AND ALK INHIBITORS IN PATIENTS WITH NSCLC WHOSE CANCERS DEVELOPED RESISTANCE TO THESE TREATMENTS NUVECTIS WILL HOLD A CONFERENCE CALL TOMORROW, TUESDAY, AUGUST 12 AT 8:30 AM ET TO DISCUSS THE ELEMENTS OF THE PHASE 1B PROGRAM AND THE OVERALL MARKET OPPORTUNITY FOR NXP900 FORT LEE, NJ, AUG. 11, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THE INITIATION OF THE PHASE 1B PROGRAM FOR NXP900. NXP900 PHASE 1B CLINICAL PROGRAM THE PHASE 1B PROGRAM WAS INITIATED FOLLOWING THE SUCCESSFUL COMPLETION OF A DOSE ESCALATION STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS AND A CLINICAL DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEER, AND IS INTENDED TO INCLUDE A SINGLE AGENT COMPONENT, WHICH IS NOW UNDERWAY, AND A COMBINATION COMPONENT THAT IS EXPECTED TO COMMENCE LATER THIS YEAR.

NUVECTIS PHARMA ANNOUNCES THE INITIATION OF THE PHASE 1B PROGRAM FOR NXP900

TAIPEI , AUG. 1, 2025 /PRNEWSWIRE/ -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) HAS UNVEILED THE I.MX 95 SERIES, THE LATEST ADDITION TO ITS POWERFUL I.MX 9 SERIES OF APPLICATION PROCESSORS.

NEXT-GEN COMPACT COMPUTER-ON-MODULES EMPOWER INTELLIGENT EDGE APPLICATIONS POWERED BY NXP I.MX 95

AVAILABLE DATA FROM 13 PATIENTS WITH RECURRENT, PLATINUM RESISTANT, ARID1A-MUTATED OVARIAN CANCER TREATED WITH 75 MG/DAY IN THE NXP800 PHASE 1B STUDY INCLUDES 2 PARTIAL RESPONSES AND 3 STABLE DISEASES; THROMBOCYTOPENIA SUCCESSFULLY MANAGED WITH INTERMITTENT DOSING SCHEDULE; OBSERVED CLINICAL ACTIVITY WARRANTS EXPLORATION OF POTENTIAL DEVELOPMENT OPPORTUNITIES IN OTHER CANCER TYPES NXP900 SUCCESSFULLY COMPLETED A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY IN HEALTHY VOLUNTEERS AND THE PHASE 1A DOSE ESCALATION STUDY; INITIATION OF THE NXP900 PHASE 1B PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF NXP900 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS EXPECTED IN THE COMING WEEKS FORT LEE, NJ, JULY 31, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY PROVIDED THE FINAL CLINICAL DATA UPDATE FROM THE PHASE 1B STUDY OF NXP800 IN RECURRENT, PLATINUM RESISTANT, ARID1A-MUTATED OVARIAN CANCER AND REPORTED ON THE PROGRESS TOWARDS THE INITIATION OF THE PHASE 1B PROGRAM FOR NXP900. AS PART OF THE NXP800 PHASE 1B STUDY, 17 PATIENTS WITH RECURRENT, PLATINUM RESISTANT, ARID1A-MUTATED OVARIAN CANCER WERE TREATED WITH NXP800 AT THE TARGET DOSE OF 75 MG/DAY, ADMINISTERED INTERMITTENTLY OR DAILY, WITH DATA AVAILABLE FOR 13 PATIENTS.

NUVECTIS PHARMA PROVIDES FINAL CLINICAL DATA UPDATE FROM THE NXP800 PHASE 1B STUDY IN OVARIAN CANCER AND REPORTS COMPLETION OF THE NXP900 PHASE 1A DOSE ESCALATION STUDY

PR NC3350C STMICROELECTRONICS TO STRENGTHEN POSITION IN SENSORS WITH ACQUISITION OF NXP'S MEMS SENSORS BUSINESS ST ENTERS INTO AGREEMENT FOR ACQUISITION OF NXP'S MEMS SENSOR BUSINESS FOR A PURCHASE PRICE OF UP TO US$950 MILLION IN CASH, INCLUDING US$900 MILLION UPFRONT AND US$50 MILLION SUBJECT TO THE ACHIEVEMENT OF TECHNICAL MILESTONES THE MEMS BUSINESSES OF ST AND NXP ARE STRONGLY COMPLEMENTARY IN TERMS OF TECHNOLOGY AND PRODUCT PORTFOLIO, WITH THE COMBINED PRODUCT OFFERING TO BE WELL BALANCED ACROSS AUTOMOTIVE, INDUSTRIAL AND CONSUMER END MARKETS NXP'S MEMS BUSINESS GENERATED REVENUE OF ABOUT US$300 MILLION IN CALENDAR YEAR 2024 WITH GROSS AND OPERATING MARGINS SIGNIFICANTLY ACCRETIVE FOR ST ALL-CASH TRANSACTION TO BE FINANCED FROM EXISTING LIQUIDITY AND EXPECTED TO BE ACCRETIVE TO ST EARNINGS PER SHARE FROM COMPLETION GENEVA, SWITZERLAND, JULY 24, 2025 -- STMICROELECTRONICS (NYSE: STM), A GLOBAL SEMICONDUCTOR LEADER SERVING CUSTOMERS ACROSS THE SPECTRUM OF ELECTRONICS APPLICATIONS, IS STRENGTHENING ITS GLOBAL SENSORS CAPABILITIES WITH THE PLANNED ACQUISITION OF NXP SEMICONDUCTORS' (NASDAQ: NXPI) MEMS SENSORS BUSINESS, FOCUSED ON AUTOMOTIVE SAFETY PRODUCTS AS WELL AS SENSORS FOR INDUSTRIAL APPLICATIONS. THE TRANSACTION WILL COMPLEMENT AND EXPAND ST'S LEADING MEMS SENSORS TECHNOLOGY AND PRODUCT PORTFOLIO, UNLOCKING NEW OPPORTUNITIES FOR DEVELOPMENT ACROSS AUTOMOTIVE, INDUSTRIAL AND CONSUMER APPLICATIONS.

Nuveen Select Tax-Free Income Portfolio

NXP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nuveen Select Tax-Free Income Portfolio

NXP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NXP